ManagementGlenmark gets US regulatory nod for anti-hypertension tablets
Glenmark Pharmaceuticals today said it has received the final approval from the US drug regulator for the marketing of its anti- hypertension tablets.
- Aurobindo Phrama gets USFDA nod for veterinary drug - Orchid Pharmaceuticals receive FDA nod for anti-migraine tablets - Ranbaxy: Catching the FDA flu - Suven hits 10% upper limit on US FDA nod - Suven gets US FDA nod for Nalgonda unit; scrip surges 10% - Ranbaxy makes voluntary recall of drug in US">Ranbaxy makes voluntary recall of drug in US
Glenmark Generics, a subsidiary firm of the company, has received the final approval from the US Food and Drug Administration (US FDA) for its hydralazine hydrochloride tablets, used for the treatment of hypertension, Glenmark Pharmaceuticals said in a filing to the Bombay Stock Exchange.
The company will immediately commence marketing and shipping its generic version in the US market, it added.
According to an estimate, as on March 2009, the market size of anti-hypertension drugs in the US was over $55 million.
Shares of Glenmark Pharma were trading at Rs 227, down 0.04 per cent in afternoon trade on the BSE.